- Home
- UFCS vs PHAR Comparison
UFCS vs PHAR Comparison
Compare UFCS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | PHAR |
|---|---|---|
| Founded | 1946 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | 409 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.4M | 917.4M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UFCS | PHAR |
|---|---|---|
| Price | $44.55 | $13.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $40.50 | $38.33 |
| AVG Volume (30 Days) | ★ 107.8K | 12.3K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ 87.45 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,386,412,000.00 | N/A |
| Revenue This Year | $11.80 | $10.04 |
| Revenue Next Year | $8.77 | $2.51 |
| P/E Ratio | ★ $38.63 | $3,041.22 |
| Revenue Growth | ★ 10.62 | N/A |
| 52 Week Low | $25.81 | $9.54 |
| 52 Week High | $49.94 | $21.34 |
Technical Indicators
Market Signals| Indicator | UFCS | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 40.26 |
| Support Level | $36.27 | $12.98 |
| Resistance Level | $49.94 | $13.44 |
| Average True Range (ATR) | 1.46 | 0.45 |
| MACD | -0.67 | 0.13 |
| Stochastic Oscillator | 0.87 | 65.80 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About PHAR Pharming Group N.V.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.